Drug Profile
Research programme: hyperbranched polyglycerol-based therapeutics - Sitka Biopharma
Alternative Names: HPG-docetaxel; Proprietary hyperbranched polyglycerols (HPG)-docetaxel; STK 01Latest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Sitka Biopharma
- Class Antineoplastics; Glycerols; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bladder cancer
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for preclinical development in Bladder-cancer in Canada (Intravesicular)
- 14 Feb 2019 Preclinical development of STK 01 is ongoing in Bladder cancer in Canada
- 28 Jul 2018 No recent reports of development identified for preclinical development in Bladder-cancer in Canada (Intravesicular)